Correlation Between Viridian Therapeutics and Kalvista Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Kalvista Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Kalvista Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viridian Therapeutics and Kalvista Pharmaceuticals, you can compare the effects of market volatilities on Viridian Therapeutics and Kalvista Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Kalvista Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Kalvista Pharmaceuticals.

Diversification Opportunities for Viridian Therapeutics and Kalvista Pharmaceuticals

0.92
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Viridian and Kalvista is 0.92. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Kalvista Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kalvista Pharmaceuticals and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Kalvista Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kalvista Pharmaceuticals has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Kalvista Pharmaceuticals go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Kalvista Pharmaceuticals

Given the investment horizon of 90 days Viridian Therapeutics is expected to under-perform the Kalvista Pharmaceuticals. In addition to that, Viridian Therapeutics is 1.01 times more volatile than Kalvista Pharmaceuticals. It trades about -0.03 of its total potential returns per unit of risk. Kalvista Pharmaceuticals is currently generating about 0.05 per unit of volatility. If you would invest  809.00  in Kalvista Pharmaceuticals on October 20, 2024 and sell it today you would earn a total of  21.00  from holding Kalvista Pharmaceuticals or generate 2.6% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Viridian Therapeutics  vs.  Kalvista Pharmaceuticals

 Performance 
       Timeline  
Viridian Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Kalvista Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Kalvista Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Viridian Therapeutics and Kalvista Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viridian Therapeutics and Kalvista Pharmaceuticals

The main advantage of trading using opposite Viridian Therapeutics and Kalvista Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Kalvista Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kalvista Pharmaceuticals will offset losses from the drop in Kalvista Pharmaceuticals' long position.
The idea behind Viridian Therapeutics and Kalvista Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Complementary Tools

Bonds Directory
Find actively traded corporate debentures issued by US companies
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stocks Directory
Find actively traded stocks across global markets